Because IGF-1R, FGFR1, and EGFR have been shown to play major roles in melanoma progression through autocrine signaling [32, 34, 36], and EGF-R, PDGFRβ, and IGF-1R have been implicated in resistance mechanisms to BRAF V600E targeted therapies [19–22, 24, 25], we were interested in validating these results. Here, PDGFRB is linked to melanoma.